WallStreetZenWallStreetZen

NASDAQ: MEIP
Mei Pharma Inc Stock

$4.24-0.01 (-0.24%)
Updated Mar 4, 2024
MEIP Price
$4.24
Fair Value Price
N/A
Market Cap
$28.25M
52 Week Low
$4.13
52 Week High
$7.97
P/E
1.43x
P/B
0.47x
P/S
0.53x
PEG
N/A
Dividend Yield
41.27%
Revenue
$72.65M
Earnings
$19.84M
Gross Margin
100%
Operating Margin
27.32%
Profit Margin
27.3%
Debt to Equity
0.32
Operating Cash Flow
-$53M
Beta
0.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MEIP Overview

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MEIP scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MEIP is good value based on its earnings relative to its share price (1.43x), compared to the US market average (36.03x)
P/E vs Market Valuation
MEIP is good value based on its earnings relative to its share price (1.43x), compared to the US Biotechnology industry average (15.95x)
P/E vs Industry Valuation
MEIP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 35 more MEIP due diligence checks available for Premium users.

Be the first to know about important MEIP news, forecast changes, insider trades & much more!

MEIP News

Valuation

MEIP fair value

Fair Value of MEIP stock based on Discounted Cash Flow (DCF)
Price
$4.24
Fair Value
$5.93
Undervalued by
28.53%

MEIP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
1.43x
Industry
15.95x
Market
36.03x
MEIP is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MEIP is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

MEIP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.47x
Industry
6.2x
MEIP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MEIP's financial health

Profit margin

Revenue
$0.0
Net Income
-$11.1M
Profit Margin
0%
MEIP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MEIP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$78.5M
Liabilities
$19.1M
Debt to equity
0.32
MEIP's short-term assets ($66.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MEIP's short-term assets ($66.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MEIP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MEIP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$11.1M
Investing
$24.5M
Financing
-$11.7M
MEIP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MEIP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MEIP$28.25M-0.24%1.43x0.47x
ICU$29.03M-0.63%-0.21x-1.83x
SRZN$27.31M+1.13%-0.77x0.60x
SLGL$29.25M-7.33%-0.96x0.68x
BIOR$29.39M+7.83%-0.13x-0.25x

Mei Pharma Stock FAQ

What is Mei Pharma's quote symbol?

(NASDAQ: MEIP) Mei Pharma trades on the NASDAQ under the ticker symbol MEIP. Mei Pharma stock quotes can also be displayed as NASDAQ: MEIP.

If you're new to stock investing, here's how to buy Mei Pharma stock.

What is the 52 week high and low for Mei Pharma (NASDAQ: MEIP)?

(NASDAQ: MEIP) Mei Pharma's 52-week high was $7.97, and its 52-week low was $4.13. It is currently -46.8% from its 52-week high and 2.66% from its 52-week low.

How much is Mei Pharma stock worth today?

(NASDAQ: MEIP) Mei Pharma currently has 6,662,857 outstanding shares. With Mei Pharma stock trading at $4.24 per share, the total value of Mei Pharma stock (market capitalization) is $28.25M.

Mei Pharma stock was originally listed at a price of $9,000.00 in Dec 18, 2003. If you had invested in Mei Pharma stock at $9,000.00, your return over the last 20 years would have been -99.95%, for an annualized return of -31.82% (not including any dividends or dividend reinvestments).

How much is Mei Pharma's stock price per share?

(NASDAQ: MEIP) Mei Pharma stock price per share is $4.24 today (as of Mar 4, 2024).

What is Mei Pharma's Market Cap?

(NASDAQ: MEIP) Mei Pharma's market cap is $28.25M, as of Mar 5, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Mei Pharma's market cap is calculated by multiplying MEIP's current stock price of $4.24 by MEIP's total outstanding shares of 6,662,857.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.